NORD supply chain intelligence for Nordicus Partners Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Nordicus Partners Corporation (NORD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BIO-CONVERT-A-S | BIO-CONVERT-A-S | 92% | On November 11, 2024, the Company entered into an agreement with Bio-Convert A/S to acquire 100% of the outstanding shares of Bio-Convert in exchange for 12,000,000 restricted shares of the Company’s… |
| OROCIDIN-A-S | OROCIDIN-A-S | 92% | On November 12, 2024, the Company acquired the remaining 5.3 % of the outstanding shares of Orocidin A/S through the issuance of 200,000 shares at $ 3.25 per share, or $ 443,708 of the Company’s Comm… |
| BIO-CONVERT | BIO-CONVERT | 90% | On November 11, 2024, the Company entered into an agreement with Bio-Convert to acquire 100 % of the outstanding shares of Bio-Convert in exchange for 12,000,000 shares of the Company’s Common Stock. |
| ESG-ADVISOR-GROUP-L-L-C | ESG-ADVISOR-GROUP-L-L-C | 90% | On November 27, 2024, the Company entered into a Professional Relations and Consulting Agreement with ESG Advisor Group, L.L.C. (“ESG”) for the provisions of investor relations and related services. |
| GOOGLE-ENTERPRISE | GOOGLE-ENTERPRISE | 90% | We utilize well-known cloud-based technologies and service providers such as Microsoft Office, and Google enterprise to provide protection against cybersecurity threats. |
| MICROSOFT-OFFICE | MICROSOFT-OFFICE | 90% | We utilize well-known cloud-based technologies and service providers such as Microsoft Office, and Google enterprise to provide protection against cybersecurity threats. |
| OROCIDIN | OROCIDIN | 90% | On November 12, 2024, the Company entered into an agreement with Orocidin to acquire the remaining 29,663 outstanding shares, or approximately 5 %, of Orocidin. In exchange, the Company issued 200,00… |
| CONSULTING-FIRM | CONSULTING-FIRM | 80% | Effective November 27, 2024, the Company entered into a consulting agreement with an advisory firm that will continue through November 30, 2025. |
| DARLINGTON-GROUP-LLC | DARLINGTON-GROUP-LLC | 80% | On October 1, 2025, the Company entered into a consulting agreement with Darlington Group, LLC, which is controlled by Andrew Ritter, a member of the Company’s board of directors. |
| ALTERAL | ALTERAL | 70% | In October 2025, the Company, through its subsidiary NoviThera, purchased intellectual property from Alteral in exchange for 49.9 % equity stake in NoviThera, to research and develop a novel and unique M |
| GK-PARTNERS-APS | GK-PARTNERS-APS | 70% | Effective April 1, 2022, we issued to GK Partners ApS ("GK Partners") , for financial services, a warrant (the "2022 GK Warrant") to purchase up to 600,000 shares of our Common Stock at an exercise p… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BIO-CONVERT-A-S | BIO-CONVERT-A-S | 92% | In June 2024, the Company signed an agreement with Bio-Convert for which it recognized $ 2,5 |
| OROCIDIN-A-S | OROCIDIN-A-S | 92% | In January 2024, the Company signed an agreement with Orocidin for which it recognized $ 2,500 in revenue during the year ended March 31, 2025. |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| NORD-DEBT-11338 | Warrants outstanding: 1000000 | 90% | xbrl warrant detail from xbrl 2025-03-31. |